TrialPath
Recruiting

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

NCT07607964 · AbbVie
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Phase 1, First-in-Human, Single Ascending Dose, Open-label, Non-randomized Study Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of ABBV-519 in Subjects With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
About this study
Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disease characterized by B cell hyperactivity. Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. The purpose of this study is to assess the pharmacokinetics, pharmacodynamics and safety of ABBV-519 in adult participants with SLE or RA. This is a single ascending dose study in an estimated 30 adult participants with moderate SLE or RA. The total duration of the study will be approximately 425 days (60-day Screening Period, 1-day Treatment Period, and a 52 week Follow-up Period) at approximately 15 to 20 sites globally. There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Eligibility criteria
Inclusion Criteria: Key Inclusion Criteria: * Individuals between 18 and 75 years of age inclusive at the time of Screening. * Minimum baseline B-cell count of 50 cells/mcL. Inclusion Criteria for SLE Participants: * Clinical diagnosis of SLE and fulfilling the 2019 EULAR/ACR classification criteria. * Positive ANA ≥ 1:80 and the presence of at least one of the following autoantibodies above the upper limit of normal (ULN): anti-double-stranded DNA (dsDNA), anti-Smith (Sm), anti-ribonucleoprotein (RNP), or anti-Sjogren's syndrome antigen A (SSA). * Hybrid Systemic Lupus Erythematosus Disease Activity Index (hSLEDAI) score of ≥ 4 (excluding anti-dsDNA and C3/C4). Lupus headache or organic brain syndrome do not count towards the hSLEDAI points required for eligibility. * Participants must have an inadequate response to ≥ 1 immunosuppressant therapies, used for at least 3 months. Inclusion Criteria for RA Participants: * Clinical diagnosis of RA and fulfilling the 2010 ACR/EULAR classification criteria for RA. * Presence of rheumatoid factor (RF) or anti-citrullinated peptide antibodies (ACPA) above the ULN. * Presence of at least 6 swollen and 6 tender joints * High-sensitivity C-reactive protein (hs-CRP) ≥ 3 mg/L. * Failed at least 1 conventional synthetic disease-modifying antirheumatic drug (DMARD) and ≥ 1 biological or targeted DMARDs of different classes. Exclusion Criteria: Key Exclusion Criteria: * Participants with a history of infection. * Participants with uncontrolled hypertension Exclusion for SLE Participants: * Active neuropsychiatric SLE, or signs or symptoms of neuropsychiatric SLE within the 6 months prior to Screening (lupus headache permissible). \- Unstable or progressive glomerulonephritis (active class III or IV). * SLE overlap syndromes including, but not limited to RA, Sjogren's disease (SjD), SSc, polymyositis, dermatomyositis, or mixed connective tissue disease. Exclusion for RA Participants: \-- History of RA overlap syndromes, including but not limited to SLE, SjD, scleroderma, mixed connective tissue disorder or polymyositis.
Study design
Enrollment target: 30 participants
Allocation: non_randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-05-28
Estimated completion: 2029-01
Last updated: 2026-11-20
Interventions
Drug: ABBV-519Drug: ABBV-519
Primary outcomes
  • • Change from Baseline in B Cells in Blood (Up to 365 Days)
  • • Maximum Plasma Concentration (Cmax) of ABBV-519. (Up to 85 Days)
  • • Time to Cmax (Tmax) of ABBV-519 (Up to 85 Days)
Sponsor
AbbVie · industry
Contacts & investigators
ContactABBVIE CALL CENTER · contact · abbvieclinicaltrials@abbvie.com · 844-663-3742
InvestigatorABBVIE INC. · study_director, AbbVie
All locations (17)
Pinnacle Research Group /ID# 278677Recruiting
Anniston, Alabama, United States
Solace Research /ID# 279155Recruiting
Tustin, California, United States
Clinical Research Of West Florida - Phase I Unit /ID# 279292Recruiting
Clearwater, Florida, United States
Finlay Medical Research - Greenacres /ID# 278380Recruiting
Greenacres City, Florida, United States
Clinical Research of Osceola /ID# 278374Recruiting
Kissimmee, Florida, United States
Allied Biomedical Research Institute /ID# 284408Recruiting
Miami, Florida, United States
Discovery Health Research Center /ID# 279691Recruiting
Plantation, Florida, United States
Clinical Research Of West Florida - Tampa - North Howard Avenue /ID# 279130Recruiting
Tampa, Florida, United States
Advanced Quality Medical Research /ID# 279147Recruiting
Orland Park, Illinois, United States
West Tennessee Research Institute - Jackson /ID# 284561Recruiting
Jackson, Tennessee, United States
Accurate Clinical Research - Houston /ID# 278382Recruiting
Houston, Texas, United States
Epic Medical Research /ID# 279180Recruiting
Red Oak, Texas, United States
Japan Community Healthcare Organization Chukyo Hospital /ID# 279611Recruiting
Nagoya, Aichi-ken, Japan
Okayama University Hospital /ID# 279763Recruiting
Okayama, Okayama-ken, Japan
Institute of Science Tokyo Hospital /ID# 279648Recruiting
Bunkyo-ku, Tokyo, Japan
Keio University Hospital /ID# 280003Recruiting
Shinjuku-ku, Tokyo, Japan
National Center for Global Health and Medicine /ID# 281191Recruiting
Shinjuku-ku, Tokyo, Japan
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA) · TrialPath